GB695787A - Improvements in anticoagulants - Google Patents
Improvements in anticoagulantsInfo
- Publication number
- GB695787A GB695787A GB3050949A GB3050949A GB695787A GB 695787 A GB695787 A GB 695787A GB 3050949 A GB3050949 A GB 3050949A GB 3050949 A GB3050949 A GB 3050949A GB 695787 A GB695787 A GB 695787A
- Authority
- GB
- United Kingdom
- Prior art keywords
- less
- ester
- salt
- sodium
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention comprises the water-soluble salts of sulphuric esters derived from dextrans of intrinsic viscosity less than 0.04, said esters having 9 per cent or more of sulphur in their sodium salts. The compounds are made by the degradation of high molecular weight dextrans, fractionation of the mixture to remove products whose intrinsic viscosity is 0.04 or more, esterifying the lower fraction with a sulphating agent and converting the ester into a water-soluble salt, e.g. of an alkali or alkaline earth metal. The ester may have up to 3 sulphate groups per glucose unit and its sodium salt preferably has 14 per cent or more sulphur. The molecular weight is less than 22,000. An example is given of the preparation of a suitable ester-salt, using chlorosulphonic acid with pyridine for the esterification and sodium hydroxide for neutralization; the product has 17.15 per cent of sulphur. Specification 603,571 is referred to. According to the Provisional Specification the dextran may be any whose molecular weight is less than 25,000.ALSO:Anticoagulants for use with blood and plasma consist mainly or entirely of a water-soluble salt of dextran sulphate, the latter being the sulphuric ester of a dextran whose intrinsic viscosity is less than 0.04; the ester has a sulphur content of not less than 9 per cent calculated on its sodium salt. The ester may have up to 3 sulphate groups per glucose unit, the molecular weight being less than 22,000. A sterile isotonic solution can be made by autoclaving a solution of the salt together with sodium chloride and a buffer, e.g. sodium bicarbonate. The salt may be of an alkali or alkaline earth metal, especially sodium. A test is described to ensure that the anticoagulants are non-toxic in vivo. Specification 603,571 is referred to. According to the Provisional Specification there may be used any dextran whose molecular weight is less than 25,000.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3050949A GB695787A (en) | 1949-11-28 | 1949-11-28 | Improvements in anticoagulants |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3050949A GB695787A (en) | 1949-11-28 | 1949-11-28 | Improvements in anticoagulants |
Publications (1)
Publication Number | Publication Date |
---|---|
GB695787A true GB695787A (en) | 1953-08-19 |
Family
ID=10308795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB3050949A Expired GB695787A (en) | 1949-11-28 | 1949-11-28 | Improvements in anticoagulants |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB695787A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0066379A2 (en) * | 1981-05-15 | 1982-12-08 | Riker Laboratories, Inc. | Composition for combating herpes virus |
-
1949
- 1949-11-28 GB GB3050949A patent/GB695787A/en not_active Expired
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0066379A2 (en) * | 1981-05-15 | 1982-12-08 | Riker Laboratories, Inc. | Composition for combating herpes virus |
EP0066379A3 (en) * | 1981-05-15 | 1983-06-08 | Riker Laboratories, Inc. | Composition for combating herpes virus |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910008329B1 (en) | Process for preparing depolymerized and super sulfated heparin | |
ES2150589T3 (en) | POLYSACCHARIDES WITH A HIGH CONTENT OF IDURONIC ACID. | |
ES8206555A1 (en) | Sulfated polysaccharides, process for their preparation and their use as medicines. | |
US3454560A (en) | Process for the production of chondroitin polysulfate | |
GB695787A (en) | Improvements in anticoagulants | |
GB603571A (en) | Compounds having a retarding action on the coagulation of blood and processes of preparing the same | |
RU2000100374A (en) | MIXTURES OF OLIGOSACCHARIDES, possessing anti-thrombotic activity | |
Jorpes et al. | On the relationship between the sulphur content and the anticoagulant activity of heparin preparations | |
GB541528A (en) | Improvements in or relating to the hydrolysis of pectin | |
GB715821A (en) | Improvements relating to the manufacture of sulphuric esters of dextran | |
GB573589A (en) | Improvements in or relating to the manufacture of alginic materials | |
Wolfrom et al. | A synthetic heparinoid from amylose | |
CHAYANSUPAP et al. | Synthesis and Bioactivities of Pectin Sulfate | |
GB740152A (en) | Sulfate esters of partially degraded chitin and salts thereof | |
GB704516A (en) | A blood anticoagulating agent and process for the manufacture thereof | |
GB746870A (en) | Preparation of sulphated chitosan | |
GB555842A (en) | Improvements in or relating to the production of pectinic acids from sugar beet pulp | |
GB620733A (en) | Improvements in and relating to carbazole derivatives | |
GB770075A (en) | Improvements in or relating to preparation of a fibrinogen product and stable solutions thereof | |
GB962585A (en) | Detergent compositions | |
GB383611A (en) | Manufacture of cellulose ethers | |
GB480096A (en) | Improvements relating to the extraction of pectins | |
GB420529A (en) | Improvements in and relating to the manufacture of cellulose esters | |
GB370497A (en) | Improvements in and relating to the manufacture of artificial mordanting substances | |
GB700721A (en) | Organic acid esters of cellulose |